{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:17:33Z","timestamp":1778505453716,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471879"],"award-info":[{"award-number":["82471879"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82311530690"],"award-info":[{"award-number":["82311530690"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82204265"],"award-info":[{"award-number":["82204265"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.biopha.2026.118974","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T14:20:58Z","timestamp":1768314058000},"page":"118974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dihydroartemisinin enhances NKG2D CAR-T cell therapy against solid tumors by inducing NKG2D ligands and remodeling the tumor microenvironment"],"prefix":"10.1016","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9739-8830","authenticated-orcid":false,"given":"Muhammad Auwal","family":"Saliu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4281-7844","authenticated-orcid":false,"given":"Mansur Dabai","family":"Salisu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rabiatu Bako","family":"Suleiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5441-5306","authenticated-orcid":false,"given":"Lawan","family":"Rabiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nada Mohamady Farouk","family":"Abdalsalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukman Olalekan","family":"Afolabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaac Adeyemi","family":"Babarinde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2818-2059","authenticated-orcid":false,"given":"Adeleye O.","family":"Adeshakin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun","family":"Wan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maoxuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib1","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-024-01625-7","article-title":"Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies","volume":"17","author":"Ai","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12943-023-01723-z","article-title":"CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances","volume":"22","author":"Maalej","year":"2023","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-019-0956-8","article-title":"Natural killer group 2D receptor and its ligands in cancer immune escape","volume":"18","author":"Duan","year":"2019","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2026.118974_bib5","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/s43018-023-00600-4","article-title":"CD8(+) T cells maintain killing of MHC-I-negative tumor cells through the NKG2D-NKG2DL axis","volume":"4","author":"Lerner","year":"2023","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib6","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s40425-019-0642-9","article-title":"T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells","volume":"7","author":"Yang","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.118974_bib7","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol."},{"issue":"8","key":"10.1016\/j.biopha.2026.118974_bib8","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","article-title":"CAR T cell combination therapies to treat cancer","volume":"42","author":"Uslu","year":"2024","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.biopha.2026.118974_bib9","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.medj.2024.03.001","article-title":"CAR-T therapy and targeted treatments: emerging combination strategies in solid tumors","volume":"5","author":"Liu","year":"2024","journal-title":"Medicine"},{"issue":"17","key":"10.1016\/j.biopha.2026.118974_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.177788","article-title":"Pharmacological induction of MHC-I expression in tumor cells revitalizes T cell antitumor immunity","volume":"9","author":"Yu","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2026.118974_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175746","article-title":"B7-H3 but not PD-L1 is involved in the antitumor effects of Dihydroartemisinin in non-small cell lung cancer","volume":"950","author":"Hu","year":"2023","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2026.118974_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175028","article-title":"Dihydroartemisinin inhibits the growth of pancreatic cells by inducing ferroptosis and activating antitumor immunity","volume":"926","author":"Zhang","year":"2022","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2026.118974_bib13","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T cell combination therapy: the next revolution in cancer treatment","volume":"22","author":"Al-Haideri","year":"2022","journal-title":"Cancer Cell Int."},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s40164-025-00621-y","article-title":"Mesothelin-targeted CAR-T cells secreting NKG2D-BiTEs exhibit potent efficacy against triple-negative breast cancer","volume":"14","author":"Saliu","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"issue":"22","key":"10.1016\/j.biopha.2026.118974_bib16","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.3390\/cells11223692","article-title":"CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.biopha.2026.118974_bib17","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.ccell.2023.11.004","article-title":"ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells","volume":"41","author":"Bergaggio","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2026.118974_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.154682","article-title":"Dihydroartemisinin elicits immunogenic death through ferroptosis-triggered ER stress and DNA damage for lung cancer immunotherapy","volume":"112","author":"Han","year":"2023","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib19","article-title":"Dihydroartemisinin-driven selective anti-lung cancer proliferation by binding to EGFR and inhibition of NRAS signaling pathway-induced DNA damage","volume":"14","author":"Li","year":"2024","journal-title":"Sci. Rep."},{"issue":"7054","key":"10.1016\/j.biopha.2026.118974_bib20","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/nature03884","article-title":"The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor","volume":"436","author":"Gasser","year":"2005","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.biopha.2026.118974_bib21","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","article-title":"ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype","volume":"113","author":"Soriani","year":"2009","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.biopha.2026.118974_bib22","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.4161\/cc.10.19.17630","article-title":"Pharmacological activation of p53 triggers anticancer innate immune response through induction of ULBP2","volume":"10","author":"Li","year":"2011","journal-title":"Cell cycle (Georgetown Tex. )"},{"key":"10.1016\/j.biopha.2026.118974_bib23","article-title":"Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy","volume":"611","author":"Kong","year":"2024","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.biopha.2026.118974_bib24","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/cancers12071760","article-title":"MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib25","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13045-020-01024-8","article-title":"Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib26","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13045-022-01364-7","article-title":"Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy","volume":"15","author":"Zhao","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2026.118974_bib27","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.immuni.2013.01.012","article-title":"Endothelial TNF receptor 2 induces IRF1 transcription factor-dependent interferon-\u03b2 autocrine signaling to promote monocyte recruitment","volume":"38","author":"Venkatesh","year":"2013","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib30","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41392-021-00506-6","article-title":"Targeting macrophages in cancer immunotherapy","volume":"6","author":"Duan","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7446","key":"10.1016\/j.biopha.2026.118974_bib31","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease","volume":"496","author":"Wynn","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.118974_bib32","article-title":"Mechanism of Dihydroartemisinin in activating macrophages to enhance host resistance to malaria","volume":"143","author":"Li","year":"2025","journal-title":"Phytomedicine Int. J. Phytother. Phytopharm."},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib33","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","article-title":"Chimeric antigen receptor macrophages (CAR-M) sensitize HER2+ solid tumors to PD1 blockade in pre-clinical models","volume":"16","author":"Pierini","year":"2025","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2026.118974_bib34","doi-asserted-by":"crossref","first-page":"950","DOI":"10.4049\/jimmunol.1400271","article-title":"Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1","volume":"193","author":"Soriani","year":"2014","journal-title":"Journal immunology (Baltimore Md. 1950)"},{"key":"10.1016\/j.biopha.2026.118974_bib35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3389\/fimmu.2018.00476","article-title":"NKG2D and Its Ligands: \"One for All, All for One\"","volume":"9","author":"Zingoni","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib36","article-title":"Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives","volume":"88","author":"White","year":"1994","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"1","key":"10.1016\/j.biopha.2026.118974_bib37","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1475-2875-10-263","article-title":"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration","volume":"10","author":"Morris","year":"2011","journal-title":"Malar. J."},{"issue":"9","key":"10.1016\/j.biopha.2026.118974_bib38","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.3390\/biomedicines13092314","article-title":"Allogeneic NKG2D CAR-T cell therapy: a promising approach for treating solid tumors","volume":"13","author":"Mukhametshin","year":"2025","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.biopha.2026.118974_bib39","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:00:24Z","timestamp":1778504424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226000065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"alternative-id":["S0753332226000065"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.118974","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dihydroartemisinin enhances NKG2D CAR-T cell therapy against solid tumors by inducing NKG2D ligands and remodeling the tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.118974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118974"}}